Henry Schein, Inc.

Report azionario NasdaqGS:HSIC

Capitalizzazione di mercato: US$8.3b

Henry Schein Crescita futura

Criteri Future verificati 1/6

Henry Schein prevede che gli utili e i ricavi cresceranno rispettivamente di 13.8% e 3.6% all'anno. Si prevede che l'EPS crescerà di 13.7% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 15.7% in 3 anni.

Informazioni chiave

13.8%

Tasso di crescita degli utili

13.71%

Tasso di crescita dell'EPS

Healthcare crescita degli utili18.3%
Tasso di crescita dei ricavi3.6%
Rendimento futuro del capitale proprio15.74%
Copertura analitica

Good

Ultimo aggiornamento06 May 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • May 08

Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next

Henry Schein, Inc. ( NASDAQ:HSIC ) shareholders are probably feeling a little disappointed, since its shares fell 5.5...
Articolo di analisi • Aug 08

Henry Schein, Inc. Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next

NasdaqGS:HSIC 1 Year Share Price vs Fair Value Explore Henry Schein's Fair Values from the Community and select yours...

Recent updates

Articolo di analisi • May 08

Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next

Henry Schein, Inc. ( NASDAQ:HSIC ) shareholders are probably feeling a little disappointed, since its shares fell 5.5...
Aggiornamento della narrazione • Apr 26

HSIC: Improving Dental Demand And Buybacks Are Expected To Support Upside

Narrative Update on Henry Schein The updated analyst price target for Henry Schein reflects a modest upward adjustment in fair value to about $90 per share, as analysts incorporate refreshed models following recent Q4 results, new initiations, and several target raises across the Street. Analyst Commentary Recent research updates on Henry Schein show a mixed but generally constructive tone, with several firms revising models after Q4 results and initial FY26 guidance.
Aggiornamento della narrazione • Apr 11

HSIC: Rising Dental Demand And New CEO Transition Are Expected To Support Upside

Henry Schein's updated analyst price target edges slightly lower to about $89, as analysts refine their models following recent Q4 results and revised long-term growth assumptions across the Street. Analyst Commentary Street research around Henry Schein has turned more constructive overall, with several firms updating models following the Q4 print and initial FY26 guidance.
Aggiornamento della narrazione • Mar 28

HSIC: Rising Dental Demand And New CEO Are Expected To Support Upside

Narrative Update on Henry Schein The updated analyst price target for Henry Schein edges up to $90.00, reflecting a series of target increases across the Street as analysts factor in better than expected Q4 results, initial FY26 guidance, refreshed models, and improved visibility on growth and end market demand. Analyst Commentary Street research on Henry Schein clusters around higher price targets following Q4 results and initial FY26 guidance, with most firms updating their models and a mix of Outperform, Overweight, Neutral, Hold, and Market Perform ratings.
Aggiornamento della narrazione • Mar 13

HSIC: Improving Dental Demand And New CEO Leadership Will Support Upside

The analyst price target for Henry Schein has been raised from $83.21 to $89.79, reflecting updated models that factor in Q4 results, initial FY26 guidance, and what analysts describe as better growth visibility and a more supportive demand backdrop. Analyst Commentary Across the Street, recent research points to a more constructive stance on Henry Schein following Q4 results and initial FY26 guidance, with several firms revising their models and resetting price targets.
Nuova narrazione • Feb 25

Cloud Software And Specialty Products Will Reshape This Healthcare Distributor’s Future Earnings Power

Catalysts About Henry Schein Henry Schein is a global distributor of dental and medical products and services with growing software, specialty and value-added solutions for healthcare providers. What are the underlying business or industry changes driving this perspective?
Aggiornamento della narrazione • Feb 25

HSIC: Steadier Dental Demand And CEO Transition Will Support Balanced Outlook

Analysts have nudged their fair value estimate for Henry Schein up from $78.14 to $83.21, citing higher Street price targets and commentary about steadier organic growth and improving dental demand as the main supports for the updated view. Analyst Commentary Recent Street research on Henry Schein leans constructive, with several firms lifting price targets and, in one case, upgrading the rating as sentiment around dental demand and organic growth improves.
Aggiornamento della narrazione • Feb 10

HSIC: Revised Assumptions And CEO Transition Will Support Balanced Earnings Outlook

Analysts have increased their price target on Henry Schein by US$7, citing updated assumptions around revenue growth, margins, and future P/E levels that contribute to a revised valuation view. Analyst Commentary Recent research behind the US$7 upward move in the price target focuses on refreshed assumptions for Henry Schein’s revenue trajectory, margin profile, and future P/E levels.
Aggiornamento della narrazione • Jan 25

HSIC: Q3 Beat And CEO Transition Will Support Range-Bound Earnings Momentum

Narrative Update: Henry Schein The analyst price target for Henry Schein has moved slightly higher by about US$0.50, as analysts point to recent price target increases and a "clean beat" in Q3 that they see as supporting a modestly higher fair value while still viewing the shares as range bound. Analyst Commentary Recent Street commentary on Henry Schein points to a mixed setup, with some bullish analysts nudging price targets higher on the back of Q3 execution and others still reluctant to see a clear path out of the stock's trading range.
Aggiornamento della narrazione • Jan 11

HSIC: Q3 Beat And AI Partnerships Will Support Range-Bound Earnings Momentum

Analysts have raised their price target on Henry Schein to US$75 from US$71, citing a clean Q3 earnings beat that they view as supporting the recent share price strength, while also questioning how much further the stock can advance beyond its recent trading range. Analyst Commentary Bullish Takeaways Bullish analysts view the Q3 result as a clean beat, which they see as supporting the recent share price move and giving the higher US$75 target some fundamental backing.
Aggiornamento della narrazione • Dec 19

HSIC: Q3 Beat And Buybacks Will Support Range-Bound Earnings Momentum

Analysts have modestly raised their price target on Henry Schein to approximately $75, reflecting a slightly higher fair value and future price-to-earnings multiple following a clean Q3 beat, even as they remain cautious about the stock meaningfully breaking out of its recent trading range. Analyst Commentary Street research following the Q3 report reflects a mix of cautious optimism and ongoing skepticism about Henry Schein's near term upside potential.
Seeking Alpha • Dec 05

Henry Schein Can Make Your Portfolio Smile

Summary Henry Schein stands out as the largest global provider of healthcare products and services for office-based dental and medical practitioners, with a strong market share. HSIC continues to deliver solid growth, reporting Q3 revenue up 5.2% year-over-year and improved profitability across all segments, driven by internal growth and targeted programs. Management anticipates ongoing revenue and EBITDA growth, supported by demographic trends, increased healthcare access, and technological advancements like AI in dental care. Shares are attractively valued relative to peers, justifying a soft "Buy" rating for this high-quality industry leader with promising expansion catalysts. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Dec 05

HSIC: Q3 Beat And Capital Returns Will Support Measured Earnings Momentum

Analysts modestly raised their price target on Henry Schein to $75 from $71, citing a clean Q3 beat that supports recent share gains while still questioning the stock's ability to break out above its historically defined trading range. Analyst Commentary Analysts highlight that the latest quarter delivered a clean beat versus expectations, reinforcing confidence in Henry Schein's ability to execute on its operating plan despite macro and industry headwinds.
Aggiornamento della narrazione • Nov 20

HSIC: Operational Improvements and Automation Are Expected to Support Earnings Momentum

Analysts have increased their price target for Henry Schein from $75 to $77, citing expectations for moderate improvements in revenue growth and future earnings. They also pointed to optimism driven by recent operating performance and strategic initiatives.
Aggiornamento della narrazione • Nov 05

HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook

Henry Schein’s analyst price target has increased from $73.23 to $75.15 per share, reflecting analysts’ confidence in improving margins and strategic initiatives following recent earnings results. Analyst Commentary Following the company's recent performance and updated guidance, research analysts have issued new commentary highlighting both upward momentum and remaining concerns regarding Henry Schein's outlook.
Articolo di analisi • Aug 08

Henry Schein, Inc. Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next

NasdaqGS:HSIC 1 Year Share Price vs Fair Value Explore Henry Schein's Fair Values from the Community and select yours...
Seeking Alpha • Mar 11

Henry Schein Looks Bullish (Technical Analysis)

Summary HSIC shows bullish price action, momentum, volume, and relative strength, making it an attractive investment with a 2.6 reward-to-risk ratio. The stock is in an uptrend, trading above its 30-week EMA, and has bullish short-term and long-term momentum as indicated by the PPO. Institutional buying supports bullish volume trends, and HSIC has been outperforming the S&P 500 since December 2024. Despite recent earnings not meeting expectations, future earnings and revenue growth, along with sector strength, indicate potential for price targets of $82.63 and $92.68. Read the full article on Seeking Alpha
Seeking Alpha • Mar 04

Henry Schein: An Industry Leader That Offers Some Upside From Here

Summary Henry Schein is the world's largest provider of healthcare products and services for office-based dental and medical practitioners, showing consistent growth through acquisitions. Despite a 3% dip in shares, management's 2025 guidance indicates continued growth, justifying a bullish stance on the stock. The firm reported a 5.8% revenue increase in Q4 2024, driven by organic growth and acquisitions, with significant improvements in net income and operating cash flow. Henry Schein's market leadership and strategic acquisitions across various healthcare segments make it a solid investment, warranting a soft 'buy' rating. Read the full article on Seeking Alpha
Seeking Alpha • Dec 10

Henry Schein: The Kind Of Business I Like But No Margin Of Safety Now

Summary Although the U.S. stock market is currently 6.9% overvalued, according to Morningstar's analysts as of December 6, 2024, there could be opportunities in undervalued sectors like healthcare. Henry Schein is a candidate surfaced by a screen in this sector. It has many characteristics that I like in companies: easy-to-understand business, and profitable, among many others. There are some short-term headwinds that investors must be aware of but not overly concerned about. No investment is so good that it is worth buying at any price, and that applies to Henry Schein, which is currently overvalued. Read the full article on Seeking Alpha
Seeking Alpha • Nov 20

Henry Schein: Another Day, Another Purchase

Summary Henry Schein announced the acquisition of Acentus, a small medical product supplier, to expand its homecare medical products platform despite recent underperformance in cash flow metrics. The CGM market, where Acentus operates, is expected to grow significantly, making the acquisition strategically sound, though financial benefits remain uncertain without disclosed terms. Despite revenue growth from acquisitions, Henry Schein's profitability metrics have declined, raising concerns about its ability to meet its revised 2024 revenue and profit targets. While Henry Schein shows potential for cost savings and slight undervaluation, persistent profitability issues and investor skepticism warrant only a cautious 'buy' rating, subject to future performance. Read the full article on Seeking Alpha
User avatar
Nuova narrazione • Aug 25

Critical Acquisitions And High-Growth Product Expansion Set To Transform Dental Giant

Expansion into high-growth products and strategic acquisitions aimed at increasing gross margins through improved integration and efficiency.
Seeking Alpha • May 23

Henry Schein: Acquisition Strategy Isn't Pulling Its Economic Weight

Summary Henry Schein, Inc. came in with flat revenue growth in Q1 FY'24, with most expansion coming from acquisitions. The company's capital allocation strategy, focused on acquisitions, is not creating economic value for shareholders in my view. Based on my analysis, the company's performance does not justify a higher valuation. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:HSIC - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202814,82958770587911
12/31/202714,26454364982915
12/31/202613,74748248862215
3/28/202613,384395391578N/A
12/27/202513,184398521712N/A
9/27/202512,938391356535N/A
6/28/202512,773389334512N/A
3/29/202512,669407508688N/A
12/28/202412,673390661848N/A
9/28/202412,499314421612N/A
6/29/202412,487352495692N/A
3/30/202412,451388473670N/A
12/30/202312,339416313500N/A
9/30/202312,693445587786N/A
7/1/202312,598458480653N/A
4/1/202312,528478387536N/A
12/31/202212,647538474602N/A
9/24/202212,607638528625N/A
6/25/202212,718650648738N/A
3/26/202212,655646656740N/A
12/25/202112,401631598710N/A
9/25/202112,236626723783N/A
6/26/202111,898606783833N/A
3/27/202110,615438544583N/A
12/26/202010,119403550599N/A
9/26/20209,622591477542N/A
6/27/20209,291585436512N/A
3/28/202010,054713683766N/A
12/28/20199,986701N/A654N/A
9/28/20199,789488N/A655N/A
6/29/20199,636444N/A597N/A
3/30/20199,504438N/A722N/A
12/29/20189,418431N/A685N/A
9/29/201810,263304N/A629N/A
6/30/201811,069352N/A586N/A
3/31/201811,812377N/A527N/A
12/30/20178,883293N/A546N/A
9/30/201712,264554N/A572N/A
7/1/201711,968550N/A619N/A
4/1/201711,782534N/A668N/A
12/31/201611,572507N/A643N/A
9/24/201611,302498N/A676N/A
6/25/201611,122492N/A605N/A
3/26/201610,879489N/A536N/A
12/26/201510,630479N/A616N/A
9/26/201510,481482N/A563N/A
6/27/201510,419469N/A630N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di HSIC ( 13.8% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di HSIC ( 13.8% all'anno) cresceranno più lentamente rispetto al mercato US ( 16.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di HSIC cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di HSIC ( 3.6% all'anno) crescerà più lentamente rispetto al mercato US ( 11.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di HSIC ( 3.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di HSIC sarà basso tra 3 anni ( 15.7 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/21 08:18
Prezzo dell'azione a fine giornata2026/05/21 00:00
Utili2026/03/28
Utili annuali2025/12/27

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Henry Schein, Inc. è coperta da 33 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jeffrey JohnsonBaird
Lawrence MarshBarclays
Glen SantangeloBarclays